|
|
|
|
|
|
|
|
|
|
"The present studies provide additional useful data on carboplatin and the feasibility of intraperitoneal infusion. Specifically, data relating to maximum tolerated dose and dose-limiting toxicity derived from these studies will be implemented in advanced phase-III research trials."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.